Chan De-Chuan, Chen Cheng-Jueng, Chu Heng-Cheng, Chang Wei-Kuo, Yu Jyh-Cherng, Chen Yu-Ju, Wen Li-Li, Huang Su-Ching, Ku Chih-Hung, Liu Yao-Chi, Chen Jenn-Han
Division of General Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
Ann Surg Oncol. 2007 Jan;14(1):84-93. doi: 10.1245/s10434-006-9091-z. Epub 2006 Oct 25.
Serum amyloid A (SAA) is a useful biomarker for gastric cancer in an animal model. We investigated the potential of SAA as a biomarker for gastric cancer in humans.
Serum levels of SAA from 96 gastric cancer patients were measured before and after curative gastrectomy; 32 patients with gastric ulcers and 52 healthy subjects were the control groups. The immunohistochemical study was performed to evaluate the protein expression over gastric cancer tissue slides.
The mean SAA concentration was higher in gastric cancer patients (88.54 +/- 50.44 mg/l) than in healthy subjects (3.36 +/- 2.29 mg/l) and gastric ulcer patients (10.48 +/- 8.97 mg/l) (P < .05). The SAA concentration was associated with tumor stage (P = .0244) and location (P = .0016) but not with Lauren's histological type (P = .839). In the multivariate analysis, SAA level was correlated with tumor location (P < .0001) and lymph node status (P < .05). During follow-up, the mean SAA concentration increased significantly in 24 patients with tumor recurrence (P < .05) but did not change in 77 patients without recurrence. In the survival analysis, patients with SAA levels > 97 mg/l had a nearly fourfold increase in risk of death. Immunoreactivity was most prominent in blood vessel regions but not within cancer cells.
These data not only demonstrated SAA was useful in predicting survival of patients with gastric cancer, but they also showed that SAA was a valuable tool for postoperative follow-up.
血清淀粉样蛋白A（SAA）在动物模型中是胃癌的一种有用生物标志物。我们研究了SAA作为人类胃癌生物标志物的潜力。
测量96例胃癌患者根治性胃切除术前和术后的血清SAA水平；32例胃溃疡患者和52例健康受试者作为对照组。进行免疫组织化学研究以评估胃癌组织切片上的蛋白表达。
胃癌患者的平均SAA浓度（88.54±50.44mg/l）高于健康受试者（3.36±2.29mg/l）和胃溃疡患者（10.48±8.97mg/l）（P<.05）。SAA浓度与肿瘤分期（P=.0244）和位置（P=.0016）相关，但与劳伦组织学类型无关（P=.839）。在多变量分析中，SAA水平与肿瘤位置（P<.0001）和淋巴结状态（P<.05）相关。在随访期间，24例肿瘤复发患者的平均SAA浓度显著升高（P<.05），而77例未复发患者的SAA浓度未改变。在生存分析中，SAA水平>97mg/l的患者死亡风险增加近四倍。免疫反应性在血管区域最为突出，但在癌细胞内不明显。
这些数据不仅表明SAA有助于预测胃癌患者的生存，还表明SAA是术后随访的一个有价值的工具。
